Natera, Inc. (NTRA)
405.92
+6.50
(+1.63%)
USD |
NASDAQ |
Oct 20, 16:00
406.00
+0.08
(+0.02%)
Pre-Market: 08:02
Natera Research and Development Expense (TTM) : 787.38M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 787.38M |
| March 31, 2026 | 705.73M |
| December 31, 2025 | 624.11M |
| September 30, 2025 | 578.38M |
| June 30, 2025 | 501.90M |
| March 31, 2025 | 444.58M |
| December 31, 2024 | 404.14M |
| September 30, 2024 | 357.64M |
| June 30, 2024 | 337.94M |
| March 31, 2024 | 327.01M |
| December 31, 2023 | 320.68M |
| September 30, 2023 | 325.62M |
| June 30, 2023 | 313.90M |
| March 31, 2023 | 318.31M |
| December 31, 2022 | 316.42M |
| September 30, 2022 | 300.32M |
| June 30, 2022 | 333.26M |
| March 31, 2022 | 304.43M |
| December 31, 2021 | 264.21M |
| September 30, 2021 | 224.78M |
| June 30, 2021 | 152.74M |
| March 31, 2021 | 122.00M |
| December 31, 2020 | 100.04M |
| Date | Value |
|---|---|
| September 30, 2020 | 82.65M |
| June 30, 2020 | 69.03M |
| March 31, 2020 | 58.15M |
| December 31, 2019 | 51.36M |
| September 30, 2019 | 49.12M |
| June 30, 2019 | 48.72M |
| March 31, 2019 | 48.45M |
| December 31, 2018 | 49.81M |
| September 30, 2018 | 50.06M |
| June 30, 2018 | 50.28M |
| March 31, 2018 | 50.21M |
| December 31, 2017 | 49.49M |
| September 30, 2017 | 47.93M |
| June 30, 2017 | 46.66M |
| March 31, 2017 | 45.18M |
| December 31, 2016 | 41.86M |
| September 30, 2016 | 38.41M |
| June 30, 2016 | 34.40M |
| March 31, 2016 | 30.84M |
| December 31, 2015 | 27.71M |
| September 30, 2015 | 24.08M |
| June 30, 2015 | 20.86M |
| March 31, 2015 | 18.42M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Guardant Health, Inc. | 375.79M |
| Myriad Genetics, Inc. | 105.80M |
| CareDx, Inc. | 79.87M |
| Caris Life Sciences, Inc. | 117.14M |
| BioRestorative Therapies, Inc. | 9.374M |